Table 3.

GBM clinical trials with temozolomide.

Author	N	Schema	Results
Stupp et al. (2005)	573	RT+temozolomide versus RT alone	Overall survival for combined modality at 2 years 27.2%, 12.1% at 4 years, and 9.8% at 5 years versus 10.9, 3, and 1.9% for radiation alone
Athanassiou et al. (2005)	110	RT+temozolomide versus RT alone	Median survival for combined modality 13 versus 8 months for radiation alone
Kocher et al. (2008)	62	RT+temozolomide versus RT alone	Median survival 15 months for combined modality versus 17 months for radiation alone